How do founder populations influence testing strategies?

How do founder populations influence testing strategies?

• A. Founder populations have no effect on testing
• B. Founder populations may have higher likelihood of specific founder mutations, justifying targeted panels
• C. Founder mutations are irrelevant to testing
• D. They only affect treatment choices

Answer: (B)

Founder populations carry mutations that trace back to a common ancestor and can be more common in that group. Because of this enrichment, testing can be tailored to look for those specific founder mutations, making the test faster, cheaper, and more likely to detect a pathogenic variant. For example, in populations with known founder BRCA1/BRCA2 mutations, a targeted panel that screens for those common variants can identify a large proportion of carriers quickly. This approach is efficient and cost-effective when the mutation spectrum in the group is well established. If a targeted test is negative but suspicion remains, clinicians can add broader sequencing to catch other, less common variants. In populations without well-defined founder mutations or with diverse ancestry, broader panels or full-gene sequencing may be needed to avoid missing important variants. So, founder populations influence testing strategies by increasing the likelihood that a targeted panel will detect the relevant mutations, guiding both test design and counseling.

Founder populations carry mutations that trace back to a common ancestor and can be more common in that group. Because of this enrichment, testing can be tailored to look for those specific founder mutations, making the test faster, cheaper, and more likely to detect a pathogenic variant.

For example, in populations with known founder BRCA1/BRCA2 mutations, a targeted panel that screens for those common variants can identify a large proportion of carriers quickly. This approach is efficient and cost-effective when the mutation spectrum in the group is well established. If a targeted test is negative but suspicion remains, clinicians can add broader sequencing to catch other, less common variants.

In populations without well-defined founder mutations or with diverse ancestry, broader panels or full-gene sequencing may be needed to avoid missing important variants. So, founder populations influence testing strategies by increasing the likelihood that a targeted panel will detect the relevant mutations, guiding both test design and counseling.